Max Healthcare Institute Limited vs Fortis Healthcare Limited
An objective side-by-side of MAXHEALTH and FORTIS, both in Healthcare: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-21 close
Latest results: MAXHEALTH Jun 2026 · FORTIS Mar 2026
At a glance
- Max Healthcare Institute Limited is the larger company by market value, about 1.5 times the size of Fortis Healthcare Limited.
- On trailing earnings, Fortis Healthcare Limited trades at the lower P/E (63.4 against 71.2).
- Max Healthcare Institute Limited earns the higher return on equity (13.6% against 10.8%).
- Over three years Fortis Healthcare Limited has grown profits faster (27% a year against 10%).
- Over the past year the share prices returned -9.3% (MAXHEALTH) and -8.6% (FORTIS).
| Metric | Max Healthcare MAXHEALTH |
Fortis Healthcare FORTIS |
|---|---|---|
| Size and price | ||
| Market cap | ₹103,813 Cr | ₹67,456 Cr |
| Share price | ₹1,067 | ₹893.50 |
| Valuation | ||
| P/E | 71.24 | 63.41 |
| P/B | 9.66 | 6.82 |
| EV/EBITDA | 46.29 | 34.01 |
| PEG | 7.12 | 2.35 |
| Dividend yield | 0.1% | 0.1% |
| Profitability | ||
| ROE | 13.6% | 10.8% |
| ROCE | 15.0% | 13.0% |
| Operating margin | 26.6% | 22.8% |
| Sales (TTM) | ₹8,712 Cr | ₹9,128 Cr |
| Net profit (TTM) | ₹1,457 Cr | ₹1,064 Cr |
| Growth | ||
| Latest quarter sales YoY | +16.7% | +17.8% |
| Latest quarter profit YoY | +4.9% | +44.1% |
| Sales CAGR 3Y | +22.0% | +13.0% |
| Profit CAGR 3Y | +10.0% | +27.0% |
| Sales CAGR 5Y | +27.0% | +18.0% |
| Profit CAGR 5Y | +60.0% | +64.0% |
| Financial strength | ||
| Debt/Equity | 0.32 | 0.35 |
| Interest cover | 7.63 | 5.20 |
| Ownership | ||
| Promoter holding | 23.7% | 31.2% |
| Promoter change (4 qtrs) | -0.03 pp | +0.00 pp |
| Price performance | ||
| Return 1M | +6.88% | -2.54% |
| Return 3M | -2.60% | -8.44% |
| Return 1Y | -9.26% | -8.61% |
| Return YTD | +2.06% | +1.07% |
| Technical condition | ||
| Technical score | 76 | 31 |
| RS rating (1-99) | 51.00 | 48.00 |
| % vs 200-DMA | +2.78% | -2.01% |
| RSI (14) | 61.95 | 44.25 |
| % from 52-week high | -12.71% | -19.09% |
